Acorda Therapeutics (ACOR) Misses Q1 EPS by 33c, Revenues Miss

Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of $0.14, $0.33 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $106.2 million versus the consensus estimate of $129.87 million.

Guidance for 2018

• The Company reiterates AMPYRA 2018 net revenue guidance of $330-$350 million. The Company expects to maintain exclusivity of AMPYRA at least through July 30, 2018; this guidance is subject to change based on the appellate court’s decision.
• R&D expenses for the full year 2018 are expected to be $100-$110 million and include manufacturing expenses associated with INBRIJA. This guidance is a non-GAAP projection that excludes share-based compensation, as more fully described below under “Non-GAAPFinancial Measures.”
• SG&A expenses for the full year 2018 are expected to be $170-$180 million. This guidance is a non-GAAP projection that excludes share-based compensation, as more fully described below under “Non-GAAP Financial Measures.”
• The Company expects to end 2018 with a projected year-end cash balance in excess of $300 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c